ロード中...
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
PURPOSE: Preclinical evidence indicates that the bone marrow microenvironment provides a protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL tyrosine kinase inhibitors (TKIs), but that targeting of the JAK-STAT pathway with the JAK2 inhibitor ruxolitinib increases...
保存先:
| 出版年: | Leuk Res |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7787269/ https://ncbi.nlm.nih.gov/pubmed/30340199 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.10.002 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|